Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIMKUNYA
- Development stage
- Approved
- Lead developer
- Bavarian Nordic
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**VIMKUNYA** is a recombinant **virus-like particle vaccine** for prevention of chikungunya disease caused by chikungunya virus in people 12 years of age and older. Originally developed by Emergent BioSolutions and later advanced by Bavarian Nordic, it contains chikungunya virus structural proteins including E1, E2, and capsid that self-assemble into non-infectious virus-like particles lacking viral genetic material. Formulated with aluminum hydroxide adjuvant and administered as a single intramuscular dose, the vaccine works by inducing neutralizing antibody responses against chikungunya virus and received United States accelerated approval based on anti-chikungunya virus neutralizing antibody data.
- Brand names
- VIMKUNYA
- Other names
- chikungunya virus VLP vaccinechikungunya virus-like particle vaccine
02
Targets
CHIKV C (Chikungunya virus capsid protein)CHIKV E2/E1 (Chikungunya virus envelope protein)
Beyond the preview
Go deeper on VIMKUNYA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIMKUNYA.